Historical Valuation
Roivant Sciences Ltd (ROIV) is now in the Fair zone, suggesting that its current forward PS ratio of 195.15 is considered Fairly compared with the five-year average of -7.65. The fair price of Roivant Sciences Ltd (ROIV) is between 10.41 to 31.95 according to relative valuation methord.
Relative Value
Fair Zone
10.41-31.95
Current Price：22.43
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Roivant Sciences Ltd (ROIV) has a current Price-to-Book (P/B) ratio of 3.47. Compared to its 3-year average P/B ratio of 3.68 , the current P/B ratio is approximately -5.80% higher. Relative to its 5-year average P/B ratio of 3.02, the current P/B ratio is about 14.82% higher. Roivant Sciences Ltd (ROIV) has a Forward Free Cash Flow (FCF) yield of approximately -5.14%. Compared to its 3-year average FCF yield of -9.88%, the current FCF yield is approximately -47.94% lower. Relative to its 5-year average FCF yield of -27.30% , the current FCF yield is about -81.17% lower.
P/B
Median3y
3.68
Median5y
3.02
FCF Yield
Median3y
-9.88
Median5y
-27.30
Competitors Valuation Multiple
AI Analysis for ROIV
The average P/S ratio for ROIV competitors is 39.33, providing a benchmark for relative valuation. Roivant Sciences Ltd Corp (ROIV.O) exhibits a P/S ratio of 195.15, which is 396.21% above the industry average. Given its robust revenue growth of -64.89%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ROIV
1Y
3Y
5Y
Market capitalization of ROIV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ROIV in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ROIV currently overvalued or undervalued?
Roivant Sciences Ltd (ROIV) is now in the Fair zone, suggesting that its current forward PS ratio of 195.15 is considered Fairly compared with the five-year average of -7.65. The fair price of Roivant Sciences Ltd (ROIV) is between 10.41 to 31.95 according to relative valuation methord.
What is Roivant Sciences Ltd (ROIV) fair value?
ROIV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Roivant Sciences Ltd (ROIV) is between 10.41 to 31.95 according to relative valuation methord.
How does ROIV's valuation metrics compare to the industry average?
The average P/S ratio for ROIV's competitors is 39.33, providing a benchmark for relative valuation. Roivant Sciences Ltd Corp (ROIV) exhibits a P/S ratio of 195.15, which is 396.21% above the industry average. Given its robust revenue growth of -64.89%, this premium appears unsustainable.
What is the current P/B ratio for Roivant Sciences Ltd (ROIV) as of Jan 09 2026?
As of Jan 09 2026, Roivant Sciences Ltd (ROIV) has a P/B ratio of 3.47. This indicates that the market values ROIV at 3.47 times its book value.
What is the current FCF Yield for Roivant Sciences Ltd (ROIV) as of Jan 09 2026?
As of Jan 09 2026, Roivant Sciences Ltd (ROIV) has a FCF Yield of -5.14%. This means that for every dollar of Roivant Sciences Ltd’s market capitalization, the company generates -5.14 cents in free cash flow.
What is the current Forward P/E ratio for Roivant Sciences Ltd (ROIV) as of Jan 09 2026?
As of Jan 09 2026, Roivant Sciences Ltd (ROIV) has a Forward P/E ratio of -15.47. This means the market is willing to pay $-15.47 for every dollar of Roivant Sciences Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Roivant Sciences Ltd (ROIV) as of Jan 09 2026?
As of Jan 09 2026, Roivant Sciences Ltd (ROIV) has a Forward P/S ratio of 195.15. This means the market is valuing ROIV at $195.15 for every dollar of expected revenue over the next 12 months.